Abstract

Pathological or functional loss of pancreatic beta cells is the cause of diabetes. Understanding how signaling pathways regulate pancreatic lineage and searching for combinations of signal modulators to promote pancreatic differentiation will definitely facilitate the robust generation of functional beta cells for curing hyperglycemia. In this study, we first tested the effect of several potent BMP inhibitors on pancreatic differentiation using human embryonic stem cells. Next, we examined the endodermal lineage bias upon potent BMP inhibitor treatment and further checked the crosstalk between signal pathways governing endodermal lineage determination. Furthermore, we improved current pancreatic differentiation system based on the signaling pathway study. Finally, we used human-induced pluripotent stem cells to validate our finding. We found BMP inhibitors indeed not only blocked hepatic lineage but also impeded intestinal lineage from human definitive endoderm unexpectedly. Signaling pathway analysis indicated potent BMP inhibitor resulted in the decrease of WNT signal activity and inhibition of WNT could contribute to the improved pancreatic differentiation. Herein, we combined the dual inhibition of BMP and WNT signaling and greatly enhanced human pancreatic progenitor differentiation as well as beta cell generation from both embryonic stem cells and induced pluripotent stem cells. Conclusively, our present work identified the crosstalk between the BMP and WNT signal pathways during human endoderm patterning and pancreas specification, and provided an improved in vitro pancreatic directed differentiation protocol from human pluripotent stem cells.

Highlights

  • Diabetes mellitus is characterized by chronic hyperglycemia due to the loss of either beta cell mass or beta cell function and could lead to severe metabolic syndrome

  • Production of functional beta cells from human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) could be a promising choice for the cell replacement therapy of diabetes

  • Human ESCs or iPSCs were seeded at the density of 30,000 to 50,000 cells per well for 24-well plate precoated with Matrigel

Read more

Summary

Introduction

Diabetes mellitus is characterized by chronic hyperglycemia due to the loss of either beta cell mass or beta cell function and could lead to severe metabolic syndrome. Human pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), could form multiple cell types and tissues composing of our body [2, 3]. Production of functional beta cells from human ESCs or iPSCs could be a promising choice for the cell replacement therapy of diabetes. A lot of efforts have been put in the last decades to direct human pluripotent stem cells to differentiate into functional beta cells in vitro and remarkable progresses have been recently achieved [4,5,6,7,8,9]. In order to generate robust beta cells from ESCs which represent the embryonic epiblast stage, pancreatic specification from differentiated definitive endoderm is a key point for the subsequent step [10]. The Nodal signaling pathway has been revealed as the main regulator of endoderm generation, but further endoderm patterning is more complicated

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call